title: [An analysis of hepatitis B virus infection rate in 405 cases of non-Hodgkin lymphoma].
abstract: OBJECTIVE
  To analyze the status of hepatitis B virus (HBV) infection in non-Hodgkin lymphoma (NHL) patients.
  
  
  METHODS
  The serum HBV markers in NHL patients were detected by enzyme-linked immunosorbent assay (ELISA). The infection rate of HBV in NHL patients was compared with that in nationwide general population.
  
  
  RESULTS
  The positive rates of HBsAg, anti-HBs and anti-HBc in 405 cases of NHL were 11.6%, 39.8% and 47.9%, respectively, which were statistically different from those in general population (P < 0.01). The positive rates of HBsAg, anti-HBs and anti-HBc in B-cell NHL and T-cell NHL were 13.3% vs 7.1% (P = 0.083), 40.6% vs 37.5% (P = 0.567), 53.2% vs 33.9% (P = 0. 001), respectively. The HBV DNA positive rate was 23.7% in 93 cases of NHL, and was 50.0% in 38 cases of HBsAg-positive NHL while 5.5% in 55 cases of HBsAg-negative but HBcAb-positive NHL.
  
  
  CONCLUSIONS
  The infection rate of HBV in NHL patients is higher than that in general population, in which occult hepatitis B virus infection can not be ignored. The positive rate of anti-HBc in B-cell NHL is significantly higher than that in T-cell NHL. For NHL patients infected with HBV, prophylactic anti-HBV therapy to prevent viral reactivation should be given before the anti-cancer treatment. Further study in the relationship between HBV and NHL should be carried out in the future.
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Liu
authors.forename: Wen
authors.initials: W
authors.lastname: Zheng
authors.forename: Xiao-Pei
authors.initials: XP
authors.lastname: Wang
authors.forename: Yu-Qin
authors.initials: YQ
authors.lastname: Song
authors.forename: Yan
authors.initials: Y
authors.lastname: Xie
authors.forename: Mei-Feng
authors.initials: MF
authors.lastname: Tu
authors.forename: Ning-Jing
authors.initials: NJ
authors.lastname: Lin
authors.forename: Ling-Yan
authors.initials: LY
authors.lastname: Ping
authors.forename: Zhi-Tao
authors.initials: ZT
authors.lastname: Ying
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: Deng
authors.forename: Chen
authors.initials: C
authors.lastname: Zhang
authors.forename: Jun
authors.initials: J
authors.lastname: Zhu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000453:epidemiology*; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000302:isolation & purification; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000821:virology*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D004279:DNA, Viral; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens